Moreover, it confirmed that intrathecal delivery of EPHA2, HER2, and IL13Rα2 CAR-T cells is an effective treatment for primary, metastatic, and recurrent group 3 medulloblastoma and PFA ependymoma in a mouse model [14]. This evidence concerns the gene ERBB2 and medulloblastoma.